Early data presented at ASCO suggest the lead mAbs against PD-1 receptor (PDCD1; PD-1; CD279) from Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co. Inc. (NYSE:MRK) could supplant Yervoy ipilimumab as first-line SOC in melanoma. BMS's Yervoy was approved based on a 3.6-month survival improvement and an impressive duration of response, with a one-year survival rate of